by Chris Lee | Jun 5, 2016 | Stock Analysis / Investing
Keryx Biopharmaceuticals (NASDAQ: KERX) As Part Of My Portfolio KERX is one of the more interesting stock in my portfolio– and it is also a growth stock that has the potential to be a multi-bagger. What is a multi-bagger? “A multibagger is an investment...
by Chris Lee | May 6, 2016 | Popular
One of the first stock that I bought was called iShares Nasdaq Biotechnology ETF (NASDAQ: IBB). I bought it on 5th February 2015 at $310.51 and sold it on 13th July 2015 at $380, netting a cool 21.39%. I like biotechnology stock and so far I have had good experience...
by Chris Lee | Apr 3, 2016 | Options
My Thought Process Nearing the end of March, one of my top stock holdings, Keryx Biopharmaceuticals (NASDAQ: KERX) announced that they had a positive result from their phase 3 study of ferric citrate for the treatment of iron deficiency anemia in adults with...
by Chris Lee | Feb 28, 2016 | Stock Analysis / Investing
With the current market capitalization of $380.27 million, Keryx (NASDAQ: KERX) might not be your cheapest company to buy in terms of having a stake in their growth story. With growth story like this, there are risks involved. Current earning is still negative...
by Chris Lee | Feb 20, 2016 | Stock Analysis / Investing
Difference Between Volatility and Risk Picture source: Google Many people associate stock market volatility with risk. Let’s be clear, volatility does not equate to risk. Volatility is the rapid and unpredictable movement of the ups and downs in the quoted stock...